Skip to content
MarketScale
‹ Back to IndustriesHealthcare

How Trends in Corporate Consolidation Reflect in Biden’s Healthcare Anti-Trust Action

Earlier this month, President Joe Biden signed an executive order that addresses competition among hospitals, health insurers, prescription drugmakers, and hearing aid manufacturers in an effort to tackle anti-competitive practices in various industries. The order urges the Department of Justice and the Federal Trade Commission to crack down on antitrust laws and actively revise merger…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

Earlier this month, President Joe Biden signed an executive order that addresses competition among hospitals, health insurers, prescription drugmakers, and hearing aid manufacturers in an effort to tackle anti-competitive practices in various industries.

The order urges the Department of Justice and the Federal Trade Commission to crack down on antitrust laws and actively revise merger guidelines to ensure patient safety. However, how will these actions impact mergers and acquisitions in general?

To further investigate this question, as well as to evaluate the incentives behind corporate consolidation in today’s economy, Daniel Litwin, the Voice of B2B, invited Dr. Susan Clark Muntean, associate professor of management and accountancy at UNC Asheville, to this episode of MarketScale TV.

The two consider what impact the trends toward M&As have had on patient access to healthcare, as well as who typically benefits from corporate mergers and acquisitions in the long term.

“That question should always be asked to look at projected outcomes and the impact of mergers and acquisitions. Who benefits, who doesn’t, and who is harmed or potentially could be harmed,” explains Dr. Clark Muntean.

They also discuss some of the responses from industry organizations to the executive order, how the primary motivators for corporate consolidation have evolved over the years and the overall effectiveness of anti-trust regulations in combatting anti-competitive practices.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Dental practice exits are turning into multi-year projects, not last-year decisions

Dental practice exits are turning into multi-year projects, not last-year decisions

Associate-led dental practice successions can take 3–5+ years. Dental Economics says associate-to-buyout timelines often run three to five-plus years. That pushes revenue-cycle controls, buy-sell terms, and tax structure earlier, before a buyer appears.

  • 01A practical benchmark is emerging for succession: bringing in an associate with intent to buy can take a minimum of three years and often more than five, according to Dental Economics.
  • 02If accounts receivable looks “high,” it may be a bookkeeping and posting problem before it is a payer problem, a revenue-cycle diagnostic Group Dentistry Now says shows up frequently at scale.
  • 03Exit planning is now an operating system project: valuation, tax positioning, and transition support belong in the same workstream, because deal structure can lock in or foreclose tax options, per Dental Economics.

Sep 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512